Jan 2018: Origin Merchant Partners Provides Fairness Opinion for the Executive Committee and Board of Aeterna Zentaris Inc. on its License and Assignment Agreement with Strongbridge Biopharma LLC

aeterna zentarisOrigin Merchant Partners was retained by the Board and Executive Committee of Aeterna Zentaris (“Aeterna” or the “Company”) to provide a fairness opinion with respect to the Company’s license and assignment agreement with Strongbridge Biopharma LLC, regarding its primary drug, Macrilen, the first FDA-approved oral drug indicated for the diagnosis of Adult Growth Hormone Deficiency.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing new treatments, principally through out-licensing arrangements.

Strongbridge Biopharma LLC. is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.

How can we help your business?

Contact us or submit an inquiry online.